Publications

March 2018 (Revised May 2018)
Supplement

Celgene (B)

By: Malcolm Baker and Emily McComb

Supplements the (A) case. View Details

Keywords: Life Sciences; Biotechnology; Public Market Investing; Celgene; Revlimid; Hedge Fund; Growth Stocks; Valuation; Investment; Decision Choices and Conditions; Analysis; Biotechnology Industry

January 2014 (Revised June 2015)
Teaching Note

Amgen Inc: Pursuing Innovation and Imitation? (A), (B)

By: Ian Mackenzie

Keywords: Strategic Change; Biosimilars; Medical Biotechnology; Emerging Markets; Industry Structure; Uncertainty; Strategy Development; Implementation; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; United States

January 2014
Supplement

Fred Khosravi and AccessClosure (C)

By: Richard Hamermesh and Lauren Barley

On September 11, 2013, the three-judge panel of the U.S. Court of Appeals for the Federal Circuit denied St. Jude's request to rehear an appeal on the "double patenting" ruling for the '439 patent. Further, it removed the injunction threat that was hanging over the... View Details

Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States

October 2013 (Revised January 2014)
Supplement

Fred Khosravi and AccessClosure (B)

By: Richard G. Hamermesh and Lauren Barley

It was January 2013, and Fred Khosravi, chairman of the board of AccessClosure Inc., wondered what the new year had in store for him and AccessClosure, the company he founded in late 2002. Khosravi was cautiously optimistic—the Mountain View, California-based medical... View Details

Keywords: Medical Devices; Vascular Closure Device; Patent Litigation; Patenting; Biomedical Research; Biotechnology; Biotech; Technological Innovation; Patents; Health Care and Treatment; Biotechnology Industry; United States; California

January 2021
Supplement

Takeda Pharmaceutical Company Limited (B)

By: David J. Collis, Nobuo Sato and Akiko Kanno

This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and... View Details

Keywords: Pharmaceutical Companies; Pharmaceuticals; M＆A; Mergers ＆ Acquisitions; Biotech; Biotechnology; R＆D; Talent Management; Mergers and Acquisitions; Globalization; Global Strategy; Talent and Talent Management; Strategy; Biotechnology Industry; Biotechnology Industry; Japan; Asia

February 2015 (Revised November 2015)
Case

Building an Integrated Biopharma Company: Crucell (A)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan S. Harmeling

By 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space,... View Details

Keywords: Biotechnology; Biopharmacy Company; Licensing; Licensing Agreements In Biopharmacy; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Partners and Partnerships; Entrepreneurship; Growth and Development Strategy; Biotechnology Industry; Biotechnology Industry; Netherlands

February 2015 (Revised November 2015)
Supplement

Building an Integrated Biopharma Company: Crucell (B)

By: Richard G. Hamermesh, Marianne Van Der Steen and Susan Harmeling

The Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8... View Details

Keywords: Biotechnology; Biopharmacy Company; Licensing Agreements In Biopharmacy; Licensing; Human Cell-line Technology; Vaccine; Healthcare Innovation; Global Health; Entrepreneurship; Health Care and Treatment; Acquisition; Innovation and Invention; Biotechnology Industry; Biotechnology Industry

January 1994 (Revised November 1997)
Case

Aberlyn Capital Management: July 1993

By: Josh Lerner and Peter Tufano

Aberlyn Capital Management, a venture leasing firm specializing in providing capital to biotechnology firms, proposes to introduce a new product. Aberlyn will base a lease on an intangible product: the patent of a biotechnology firm. This poses a series of short and... View Details

Keywords: Financing and Loans; Valuation; Product Launch; Problems and Challenges; Patents; Financial Instruments; Biotechnology Industry; Biotechnology Industry

November 2002 (Revised June 2003)
Case

Monsanto: Leadership in a New Environment

By: Ray A. Goldberg, James Weber and James M Beagle

Monsanto is the biotechnology leader in agriculture. How does it use its leadership in Round Up to fund long-term research and development in biotechnology that is acceptable to the priority system of consumers in different parts of the world? Includes color exhibits. View Details

Keywords: Research and Development; Science-Based Business; Food; Business or Company Management; Agribusiness; Industry Growth; Customer Focus and Relationships; Globalization; Leadership; Biotechnology Industry; Biotechnology Industry; United States

07 Apr 2016
News

Sanofi Genzyme Donates Corporate Archives to Harvard Business School

October 2002
Case

A Father's Love: Novazyme Pharmaceuticals, Inc.

By: Richard M.J. Bohmer and Bradley Campbell

John Crowley, CEO of Novazyme Pharmaceuticals, a start-up biotechnology firm developing an orphan drug to treat a rare lysosomal storage disorder from which his children suffer, must choose between a partnership and a buyout to have sufficient funds and support to get... View Details

Keywords: Technological Innovation; Business Startups; Partners and Partnerships; Financing and Loans; Governing Rules, Regulations, and Reforms; Sales; Price; Product Development; Motivation and Incentives; Decision Choices and Conditions; Biotechnology Industry; Biotechnology Industry

13 Jan 2003
Research & Ideas

Making Biotech Work as a Business

for example, was a banner year for bad news, with thirty late-stage clinical failures of biotech drugs, he said. The online magazine Signals, which is published by Recombinant Capital, a consulting firm that works on biotechnology... View Details

Keywords: by Martha Lagace; Biotechnology; Biotechnology; Biotechnology

February 2010 (Revised September 2011)
Case

Roche's Acquisition of Genentech

By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain

Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and... View Details

Keywords: Mergers and Acquisitions; Business Subsidiaries; Negotiation Offer; Organizational Culture; Corporate Strategy; Biotechnology Industry; Biotechnology Industry; Switzerland

26 Apr 2023
Video

Harvard MS/MBA Information Session and Virtual Q&A

15 Nov 2024
Video

MS/MBA Information Session

25 Jun 2019
Blog Post

Learning the Language of Business and Science – The MS/MBA Biotechnology: Life Sciences Program

My path into the field of biotechnology began at a young age. I was largely influenced by my mother, who is a chemical engineer with an MBA, and by my upbringing in Boston, which exposed me to one of the top biotech/healthcare... View Details

November 2008
Case

Adnexus Therapeutics, Inc.: Considering the Exit

By: Vicki L. Sato and Rachel Gordon

Dr. John Mendlein, CEO of Adnexus Therapeutics Inc. (Adnexus), a private biotechnology company, must decide whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six-month collaboration or continue with Adnexus' planned IPO. View Details

Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Entrepreneurship; Initial Public Offering; Corporate Strategy; Biotechnology Industry